ReviewInternational journal of molecular sciences2020
The Role of Endocan in Selected Kidney Diseases.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The predictive value of endocan as a novel biomarker: an umbrella study on meta-analyses.Systematic reviews · 2025Pooled it
- Biomarkers and Endothelial Damage in Obesity: An Insight into the Pharmacological Modulation.International journal of molecular sciences · 2026Review
- Serum Endocan Levels as a Risk Factor for Peripheral Artery Disease in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5.Medicina (Kaunas, Lithuania) · 2025Article
- The Relationship between Vascular Biomarkers (Serum Endocan and Endothelin-1), NT-proBNP, and Renal Function in Chronic Kidney Disease, IgA Nephropathy: A Cross-Sectional Study.International journal of molecular sciences · 2024Article
- Oncogenic HPV-induced high expression of ESM1 predicts poor prognosis and regulates aerobic glycolysis in cervical cancer.iScience · 2024Article
- Endocan, a novel glycoprotein with multiple biological activities, may play important roles in neurological diseases.Frontiers in aging neuroscience · 2024Review
- Endocan as a Potential Marker for Predicting All-Cause Mortality in Hemodialysis Patients.Journal of clinical medicine · 2023Article
- Endocan in prediabetes, diabetes, and diabetes-related complications: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2023Article
- Machine learning algorithm-based identification and verification of characteristic genes in acute kidney injury.Frontiers in medicine · 2022Article
- Prognostic and Diagnostic Value of Endocan in Kidney Diseases.International journal of nephrology · 2022Review
- Kidney Inflammation, Injury and Regeneration 2020.International journal of molecular sciences · 2021Article
- Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Endocan, previously referred to as an endothelial-cell-specific molecule-1 (ESM-1) is a member of a proteoglycan family that is secreted by vascular endothelial cells of different organs, mainly lungs and kidneys. It is assumed to participate in endothelial activation and the triggering of inflammatory reactions, especially in microvasculatures. Thanks to its solubility in human fluids, i.e., urine and blood plasma, its stability and its low concentrations in physiological conditions, endocan has been proposed as an easily available, non-invasive biomarker for identifying and predicting the course of many diseases. Recently, endocan has been studied in relation to kidney diseases. In general, endocan levels have been linked to worse clinical outcomes of renal dysfunction; however, results are conflicting and require further evaluation. In this review, authors summarize available knowledge regarding the role of endocan in pathogenesis and progression of selected kidney diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.